Anzeige
Erschienen in:
30.05.2016 | Original Article
Combination of infliximab with thiopurines significantly reduces white cell and neutrophil counts in inflammatory bowel disease patients
Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2017
Einloggen, um Zugang zu erhaltenAbstract
Background
The effects of thiopurines on white cell count are well documented.
Objective
We compared the effects of infliximab 5 mg/kg monotherapy and combination of infliximab with thiopurines on the total and differential white cell count (WBC).
Methods
13 IBD patients treated with infliximab monotherapy and 18 IBD patients treated with a combination of infliximab and thiopurines were included in the study. Using retrospective data, cell counts were examined prior to induction of infliximab, and at 6 weeks and 1 year post-induction.
Results
The patients on combination therapy had an absolute WBC at 52 weeks of 5.7 whereas that of patients on Infliximab monotherapy at the same time point was 8.3 with comparable neutrophil count of 3.4 and 5.4. The results showed a significant reduction in white cell count and neutrophils at 6 weeks which persisted at 52 weeks in both groups (p < 0.05) with a greater drop in patients on combination infliximab and thiopurine (p < 0.05) as compared to Infliximab monotherapy. There was no significant change in the lymphocyte count.
Conclusion
Full blood counts should be closely monitored in all patients starting infliximab therapy, in particular patients receiving concomitant thiopurines.